Hepatitis C Virus NS5A Inhibitor [EPC]

43367 reported adverse events

Drugs of this class: LEDIPASVIR AND SOFOSBUVIR VELPATASVIR AND SOFOSBUVIR ELBASVIR AND GRAZOPREVIR GLECAPREVIR AND PIBRENTASVIR SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR

These side effects are most commonly reported by patients taking drugs of the Hepatitis C Virus NS5A Inhibitor [EPC] class:

# Side effect Count
0 FATIGUE 10031
1 HEADACHE 8643
2 NAUSEA 3827
3 DIARRHOEA 2230
4 INSOMNIA 1705
5 DRUG INEFFECTIVE 1665
6 HEPATITIS C 1329
7 PRURITUS 1121
8 VOMITING 1102
9 DRUG DOSE OMISSION 1039
See all common reactions for Hepatitis C Virus NS5A Inhibitor [EPC]

Drugs of the Hepatitis C Virus NS5A Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HEPATITIS C VIRUS TEST POSITIVE 160 0.3245
1 VIRAL LOAD UNDETECTABLE 12 0.2308
2 HEPATIC CANCER RECURRENT 46 0.2091
3 GENOTYPE DRUG RESISTANCE TEST POSITIVE 186 0.2062
4 HEPATITIS C RNA 7 0.1944
5 HEPATITIS C RNA POSITIVE 29 0.1847
6 HEPATITIS C 1329 0.1225
7 VIRAL LOAD 14 0.1053
8 VIRAL LOAD DECREASED 12 0.0952
9 HEPATOCELLULAR CARCINOMA 515 0.0888
See all enriched reactions for Hepatitis C Virus NS5A Inhibitor [EPC]